This morning, positive results from a phase 2a study testing an experimental asthma drug developed by biotech Regeneron (REGN 0.37%) and big pharma company Sanofi (SNY 1.84%) were published in the New England Journal of Medicine. In the following video, health-care analyst Max Macaluso discusses the details of the trial and offers his long-term view on both stocks.